Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …

A dynamic interplay exists between host and tumor, and the ability of the tumor to evade
immune recognition often determines the clinical course of the disease. Significant …

Background Endogenous or iatrogenic antitumour immune responses can improve the
course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour …

Abstract αE (CD103) β7 is a TGFβ-regulated integrin that mediates retention of lymphocytes
in peripheral tissues by binding to E-cadherin expressed on epithelial cells. We recently …

Purpose: In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by
malignant cells and tumor infiltration by immune cells expressing coinhibitory receptors such …

Background Recently, unprecedented clinical efficacy was observed during treatment of
many solid tumors because of the introduction of programmed cell death 1 (PD …

The adaptive immune system is clearly capable of recognizing and attacking malignant
plasma cells in patients with multiple myeloma (MM). However, MM patients evidence …

Cancers can evade the host immune system by inducing upregulation of immune inhibitory
signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory …

In follicular lymphoma, studies addressing the prognostic value of microenvironment-related
immunohistochemical markers and tumor cell-related genetic markers have yielded …

Extranodal natural killer/T‑cell lymphoma (ENKL) is marked by a profound cellular immune
deficiency that may influence the capacity of T cells to extract an efficient antitumor immune …